The U.S. FDA is proposing new pathways aimed at cutting time to first-in-human studies, using the 2027 budget to support more streamlined trial entry for sponsors with adequate preclinical packages. The plan would make certain elements of the development process less burdensome by introducing an optional, risk-based expedited Investigational New Drug pathway and potentially expanding flexibility for early-stage trial planning. The budget proposal also emphasizes “radical transparency” and a shift toward a more proactive regulatory posture. A related reporting brief notes the FDA’s approach is designed to accelerate development schedules and reduce cost—particularly in contexts where companies want to confirm key preclinical findings without repeating high-friction steps such as certain animal testing. For the biotech sector, the practical impact will depend on congressional approval, operational details, and how broadly the agency defines “adequate” preclinical data for expedited pathways.